Oculis Holding Ag OCS

$7.64 +0.14 (1.87%)

Valuation

Market cap
442,998,000
Revenue TTM
$1,450,000
Net income TTM
$-119,440,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-8,237.24%
Debt to equity
0.00

Trading

Volume
183,900
Avg volume
298,398
Day's range
$7.28 – $7.68
Shares out
57,984,000
Stochastic %K
68%
Beta
0.67
Analysts
Strong Buy
Price target
$36.90

Price

Company profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2...

Show more

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.

Industry
Biotechnology
Sector
Healthcare
Phone
41 41 711 3960
Website
https://oculis.com
Address
Bahnhofstrasse 20, Zug, Switzerland

Latest news

Stocktwits

Merlintrader Nov 13, 6:45 PM
$OCS Oculis hosts an R&D Day in New York on Dec 8. Topline from the PREDICT-1 registrational trial of licaminlimab in dry eye disease is expected around year-end. Not investment advice. Catalysts, financials and the latest filings in our $OCS stock hub: https://www.merlintrader.com/oculis-holding-ag-stock-hub/
0 replies
GTA_Terminal Nov 9, 12:33 PM
Dark pool check on $OCS: what traded off the exchanges in the latest session. That came on a day the stock jumped hard, so the question is whether big holders were chasing it or selling into it. Read the full article for the full details: https://globaltradersacademy.com/articles/ocs-technical-levels-chart-options-flow-and-dark-pools-diverge-at-7-49?utm_source=stocktwits&utm_medium=social
0 replies
Merlintrader Nov 4, 3:37 PM
$OCS — Oculis amends its at-the-market agreement: capacity to sell up to $125M of shares, after $61.3M sold. Q3 net loss CHF 18.2M; cash and deposits CHF 210.3M (about US$252M). OCS Stock Hub: Oculis Holding News, Eye-Disease Pipeline and Clinical Data https://www.merlintrader.com/oculis-holding-ag-stock-hub/
0 replies
STACKD0E Nov 1, 11:16 PM
$AGIO $RXRX $OCS 👁
0 replies
Merlintrader Oct 29, 2:48 PM
$OCS Oculis news: Presentations on privosegtor/PIONEER at APOIS and ACUITY data at the CNS Summit, Nov 2-3. $OCS closed at $7.98 on Wednesday, below the 50-day SMA ($9.95) and below the 200-day ($18.97). Daily RSI 40. OCS hub: https://www.merlintrader.com/oculis-holding-ag-stock-hub/ Interactive chart with bull and bear scenarios on JC Just Charts: https://justcharts.merlintrader.com/#OCS Not investment advice.
0 replies
Compassbuyer Oct 27, 7:19 PM
$OCS if you bought at 20$+, brrrr... but don't give up!
0 replies
Compassbuyer Oct 27, 6:57 PM
$OCS 5$ by the end of the year... that's the price I'll get some... hopefully it recovers in Q2 2027.
0 replies
caronte Oct 23, 6:17 PM
$OCS let's keep in mind this ticker value is 30-40$
0 replies